Atorvastatin prevents glomerular extracellular matrix formation by interfering with the PKC signaling pathway.

about

Atorvastatin prevents glomerular extracellular matrix formation by interfering with the PKC signaling pathway.

Item

http://www.wikidata.org/entity/Q52726924

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Atorvastatin prevents glomerul ...... ith the PKC signaling pathway.

@en

Atorvastatin prevents glomerul ...... ith the PKC signaling pathway.

@nl

type

Item

label

Atorvastatin prevents glomerul ...... ith the PKC signaling pathway.

@en

Atorvastatin prevents glomerul ...... ith the PKC signaling pathway.

@nl

prefLabel

Atorvastatin prevents glomerul ...... ith the PKC signaling pathway.

@en

Atorvastatin prevents glomerul ...... ith the PKC signaling pathway.

@nl

P1476

Atorvastatin prevents glomerul ...... ith the PKC signaling pathway.

@en

P2093

Fan Yang

http://www.w3.org/2001/XMLSchema#string

Qing Han

http://www.w3.org/2001/XMLSchema#string

Su-Xian Zhou

http://www.w3.org/2001/XMLSchema#string

Xiao-Yun He

http://www.w3.org/2001/XMLSchema#string

Yan-Hua Xiao

http://www.w3.org/2001/XMLSchema#string

P2860

Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method

Toll-like receptor activation: from renal inflammation to fibrosis

The role of platelet-activating factor in mesangial pathophysiology

Characterization of the de novo biosynthetic enzyme of platelet activating factor, DDT-insensitive cholinephosphotransferase, of human mesangial cells

Platelet-activating factor receptor

A PRISMA-compliant systematic review and meta-analysis of randomized controlled trials investigating the effects of statin therapy on plasma lipid concentrations in HIV-infected patients.

Quantification of HDL proteins, cardiac events, and mortality in patients with type 2 diabetes on hemodialysis.

Role of histamine and platelet-activating factor in allergic rhinitis.

Lipid-lowering drugs.

Impact of atorvastatin treatment on platelet-activating factor acetylhydrolase and 15-F(2trans)-isoprostane in hypercholesterolaemic patients.

P304

6441-6448

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3892/MMR.2018.8724

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-03-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29532876

http://www.w3.org/2001/XMLSchema#string

P932

5928626

http://www.w3.org/2001/XMLSchema#string